Work

Abstract PS5-01-14: Trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd + pertuzumab in patients (pts) with previously untreated HER2+ unresectable/metastatic breast cancer (mBC): final results from DESTINY-Breast07

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-01-14

Authors: F. André, E. Hamilton, S. Loi, C. Anders, P. Schmid, E. Artamonova, R. Villanueva-Vázquez, J. Pedrini, D. Doval, S. C. Chen, S. Boston, A. Konpa, M. Markowska, G. Fabbri, K. Jhaveri

Institutions: Université Paris-Saclay, Institut Gustave Roussy, Sarah Cannon, Peter MacCallum Cancer Centre, Duke University, Duke Cancer Institute, Queen Mary University of London, Barts Cancer Institute, Russian Cancer Research Center NN Blokhin, Institut Català d'Oncologia, Grupo Hospitalar Conceição, Rajiv Gandhi Cancer Institute and Research Centre, Linkou Chang Gung Memorial Hospital, AstraZeneca (United States), AstraZeneca (Poland), Memorial Sloan Kettering Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129618444

Cites:

Cited by:

Related to: